View in EDS PDF Full Text

Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).

Saved in:
Bibliographic Details
Title: Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
Authors: Fung AT; Vitreous-Retina-Macula Consultants of New York and LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY 10022, USA., Kumar N, Vance SK, Slakter JS, Klancnik JM, Spaide RS, Freund KB
Source: Eye (London, England) [Eye (Lond)] 2012 Sep; Vol. 26 (9), pp. 1181-7. Date of Electronic Publication: 2012 Aug 10.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 22878451
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid &amp;lt;30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Fung+AT%22&quot;&gt;Fung AT&lt;/searchLink&gt;; Vitreous-Retina-Macula Consultants of New York and LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY 10022, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Kumar+N%22&quot;&gt;Kumar N&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Vance+SK%22&quot;&gt;Vance SK&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Slakter+JS%22&quot;&gt;Slakter JS&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Klancnik+JM%22&quot;&gt;Klancnik JM&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Spaide+RS%22&quot;&gt;Spaide RS&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Freund+KB%22&quot;&gt;Freund KB&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%228703986%22&quot;&gt;Eye (London, England)&lt;/searchLink&gt; [Eye (Lond)] 2012 Sep; Vol. 26 (9), pp. 1181-7. &lt;i&gt;Date of Electronic Publication: &lt;/i&gt;2012 Aug 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov&#39;t
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: &lt;i&gt;Publisher: &lt;/i&gt;&lt;searchLink fieldCode=&quot;PB&quot; term=&quot;%22Nature+Publishing+Group%22&quot;&gt;Nature Publishing Group &lt;/searchLink&gt;&lt;i&gt;Country of Publication: &lt;/i&gt;England &lt;i&gt;NLM ID: &lt;/i&gt;8703986 &lt;i&gt;Publication Model: &lt;/i&gt;Print-Electronic &lt;i&gt;Cited Medium: &lt;/i&gt;Internet &lt;i&gt;ISSN: &lt;/i&gt;1476-5454 (Electronic) &lt;i&gt;Linking ISSN: &lt;/i&gt;&lt;searchLink fieldCode=&quot;IS&quot; term=&quot;%220950222X%22&quot;&gt;0950222X &lt;/searchLink&gt;&lt;i&gt;NLM ISO Abbreviation: &lt;/i&gt;Eye (Lond) &lt;i&gt;Subsets: &lt;/i&gt;MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=22878451
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/eye.2012.174
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1181
    Titles:
      – TitleFull: Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid &lt;30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fung AT
      – PersonEntity:
          Name:
            NameFull: Kumar N
      – PersonEntity:
          Name:
            NameFull: Vance SK
      – PersonEntity:
          Name:
            NameFull: Slakter JS
      – PersonEntity:
          Name:
            NameFull: Klancnik JM
      – PersonEntity:
          Name:
            NameFull: Spaide RS
      – PersonEntity:
          Name:
            NameFull: Freund KB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2012 Sep
              Type: published
              Y: 2012
          Identifiers:
            – Type: issn-electronic
              Value: 1476-5454
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Eye (London, England)
              Type: main
ResultId 1